Down Syndrome

When deciding whether traditional prenatal screening for fetal chromosomal abnormalities including Down Syndrome (trisomy 21) is worth the potential complications, it can be difficult to weigh the options and risks. Luckily, there are now safe and easy-to-administer alternatives to amniocentesis that offer close to 100% accurate detection of Down Syndrome and related disorders, including Patau Syndrome and Edwards' Syndrome. The innovative, entirely non-invasive prenatal screening kit developed by Eurofins Biomnis is a simple genetic test for pregnant women at risk of trisomy 13, 18, and 21. These reliable and safe NIPT tests quickly and effectively detect all three of these common complications, and offer expectant parents peace of mind, early on.

Available starting from only the tenth week of pregnancy, theEurofins Biomnis NIPT Down Syndrome test offers effective prenatal testing, detecting risks for Trisomy 21 as well as related abnormalities with an almost 100% rate of accuracy. The genetic test is performed by drawing a simple maternal blood sample. Aside from maternal DNA, maternal blood contains fetal DNA originating from the placenta. The identification of fetal DNA in this sample, in tandem with a new technology capable of counting all genetic material sequences within it, allows for an extremely accurate detection of abnormalities. Opting for a NIPT Down Syndrome test may allow you to limit or entirely forgo invasive screening procedures.

While patients may assume that Down Syndrome screening is necessarily a complicated medical procedure, this innovative non-invasive prenatal test is in fact remarkably simple to prescribe and administer. It can be prescribed by your healthcare provider; and you can either have your physician administer it or take the test at a Eurofins Biomnis partner laboratory. It can be prescribed early in your pregnancy, after only 10 weeks of pregnancy. With results of the blood test generally available after 7 working days, NIPT by Eurofins Biomnis is an efficient, safe, and remarkably accurate way to undergo Down Syndrome screening. It has been found to reduce unnecessary invasive sampling by up to 95%.